Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Targeted Oncology|July 21, 2019
Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus ExemestaneAnnelieke E C A B Willemsen, Jolien Tol, Nielka P van Erp, et al.
Molecular Oncology|March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatmentEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicityNielka P van Erp, Karel Eechoute, Astrid A van der Veldt, et al.
European Urology Oncology|March 14, 2024
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate CancerEmmy Boerrigter, Joanneke K Overbeek, Guillemette E Benoist, et al.
Clinical Pharmacokinetics|November 16, 2024
A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age GroupsMa Ida Mohmaed Ali, A Laura Nijstad, René J Boosman, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 14, 2022
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancerNiels A D Guchelaar, Ruben A G van Eerden, Stefanie L Groenland, et al.
The Lancet. Oncology|August 1, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required dosesCatharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
Cancer Chemotherapy and Pharmacology|January 17, 2025
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinomaMarinda Meertens, Eline L Giraud, Esbar Hassan, et al.
International Journal of Cancer|January 11, 2021
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposureStefanie D Krens, Floor J E Lubberman, Marthe van Egmond, et al.
Therapeutic Drug Monitoring|August 25, 2022
Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and ToxicityRien H L Hoge, Suzan E H Detert Oude Weme, Walter L Vervenne, et al.
Pageof 11